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1029-195 Does Genetic Polymorphism for Platelet Glycoprotein 
llla Impact Early and Long-Term Outcomes After 
Elective Percutaneous Coronary Interventions? 
POSTER SESSION 
Giora Weisz, Roxana Mehran, Eugenia Nikolsky. Eve D. Aymong, Sotir Polena, lzat 
Hjazi, lssam Moussa, Edward Kreps, Gregg W. Stone, Jeffrey W. Moses, Martin 6. Leon, 
George Dangas, Lenox Hill Hospital Heart and Vascular Institute of New York and 
Cardiovascular Research Foundation, New York, NY 
Background: Genetic polymorphism (PI A2) of the platelet GPllla protein has been 
associated with increased thrombosis and myocardial infarctnon compared to the Al Al 
status; the rare A2A2 status confers the greatest risk, while the AlAZ status confers 
rather modest risk. The association of PI A2 with adverse events after percutaneous cor- 
onary intervention (PCI) is unknown. 
Patients and Methods: We followed 153 consecutive patients with normal baseline CK- 
MB, who underwent elective PCI for symptomatic coronary artery disease for 1 year. All 
patients were tested for PI A2 polymorphism. Adverse events were recorded and adjudi- 
cated by an independent committee blinded to the polymorphism status. All patients 
received ASA and Clopidogrel for one month post PCI. 
Results: The normal (AIAI) and heterozygous (Al AZ) variants were found in 106 
(70.6%) and 45 (29.4%) of the patients respectively; the homozygous variant was not 
detected in this population. Baseline patient and lesion characteristics, as well as platelet 
aggregation assay, maximum activated cloting time value and use of GP Ilb/llla blockers 
were similar between the 2 groups. There were no differences in outcome between 
groups (Table). 
Conclusions: Heterozygous genetic polymorphism PI Al A2 was found in approximately 
one third of patients undergoing elective PCI and it was not associated with any increase 
in early or late adverse outcomes after PCI compared to the normal homozygous PI 
AIAI status. 
AlAl, n=108 AlA2,n=45 p-Value 
Intra-procedural no flowlthrombus 1 (1%) 0 (0%) 1.0 
Any CPK-MB elevation (> normal) 23 (21%) 9 (20%) 0.65 
CPK-MB elevation (r5 X normal) 1 (1%) 2 (4%) 0.21 
MACE at 30-days 4 (3.7%) 0 (0%) 0.32 
MACE at 1 year 6.6% 7.9% 0.72 
1029-196 Diabetics Achieve Lower Activated Clotting Time When 
Given the Same Dose of Heparin as Nondiabetics 
During Percutaneous Coronary Intervention 
Michael S. Lee, Varinder Singh, Salvatore Aametta, Tom Nero, Marshal Fox, James Ft. 
Wile&. St. Luke’s_Roosevelt Hospital Center, New York, NY 
Background: It is well established that adverse clinical outcomes and complications of 
percutaneous coronary intervention (PCI) are more common in diabetics than in non-dia- 
betics. The use of glycoprotein llblllla receptor antagonists has improved clinical out- 
comes. Current PCI guidelines recommend an initial 70 ItJlkg intravenous dose of 
heparin to reach an activated cloning time (ACT) level of 300 to 350 s with the Hemo- 
chrorv8 device. Diabetics may be less sensitive to heparin compared to non-diabetics. 
We hypothesized that an initial heparin dose of 70 IU/kg is not sufficient to adequately 
anticoagulate diabetics undergoing PCI. 
Methods: We retrospectively studied 265 PCI patients treated by intention to receive 70 
IU/kg of unfractionated heparin, and compared initially-achieved ACT in diabetics versus 
non-diabetics. 
Results: Other than the presence or absence of diabetes, there was no statistical differ- 
ence in the baseline characteristics in the two groups. Mean heparin dose given per kg 
was the same in diabetics and non-diabetics (69.1ill.9 vs. 70.2*10.7 IU/kg, p=O.44). 
Achieved initial ACT in the diabetic group was significantly lower than that I” the non-dia- 
betic group (269.5k46.5 vs. 333.6i53.6 s, pcO.001). The results suggest that diabetics 
are less sensitive to unfractionated heparin and have lower ACT levels than non-diabet- 
ics when administered standard weight-dosed heparin. 
Conclusions: Current heparin dosing of 70 IU/kg for PCI leads to suboptimal initial ACT in 
diabetics. Diabetics may need a higher dose of unfractionated heparin to reach optimal 
levels of anticoagulation during PCI. Further investigation is warranted to determine opti- 
mal combinations of antithrombotic and antiplatelet therapies especially in diabetic 
patients. 
1030 Coated Stents 
Sunday, March 30, 2003, NoonQ:OO p.m. 
McCormick Place, Hall A 
Presentation Hour: Noon-l:00 p.m. 
1030-l 78 Sirolimus-Eluting Stent for Treatment of In-Sjtent 
Restenosis: One-Year Angiographic and Intravascular 
Ultrasound Follow-Up 
Kenqo Tanabe. Degertekin Muzaffer, Evelyn Regar, Chi-hang Lee, Pieter C. Smits. 
Willem J. van der Giessen. Pim de Fevter. Jeffrev J. Pooma. Patrick W. Serruvs. 
I .  I  I  
Thoraxcenter, Rotterdam, The Netherlands, Brigham &Women’s Hospital, Boston, MA 
Background: We have previously reported that sirolimus-eluting stems (SES) prevent 
neointimal formation and recurrent restenosis in the treatment of in-stent restenosis (ISR) 
at 4 months after procedure. The aim of this study was to investigate whether the benefi- 
cial effect could be maintained up to 1 year after procedure. 
Methods Patients with severe, recurrent ISR in a native coronary artery and objective 
evidence of ischemia were recruited. They received one or more 16mm sirolimus-eluting 
Bx VELOCITY stems. Quantitative angiographic and 3D IVUS follow-up was performed 
at 4 months and at 1 year. 
Results: A total of 16 patients were recruited including 4 patients with recurrent resteno- 
sis following brachyiherapy aid 1 heart transplant recipient. The average length of the 
restenotic segment was 18.4 f 13.lmm: 3 lesions were focal, 5 diffuse, 5 proliferative 
and 3 total occlusion of the stem. Satisfactory angiographic results were achieved in 15 
out of 16 patients. In one patient who received two SESs in an occluded obtuse marginal 
branch of the circumflex artery. adequate stent expansion could not be achieved despite 
the use of high pressure (24 atm). All patients were discharged without complication 1 
day after the procedure. At 4 month follow-up, 3 patients had anglographic evidence of 
restenosis (1 in-stem and 2 in-lesion) without need for repeat revascularization. The in- 
stent late lumen loss and the volume obstruction of the stem by IVUS was 0.2lmm and 
1.1%. respectively. To date, 3 patients had experienced 4 major adverse cardiac events 
(2 deaths (one sudden death and one heart failure), 1 acute myocardial infarction neces- 
sitating repeat target vessel angioplasty). So far, 7 patients have completed 1 year angio- 
graphic follow-up. The quantitative measurement will be available at the time of 
presentation. 
Conclusion: In this study it will be evaluated whether the beneficial effect of SES in 
patients with severe ISR can be maintained up to 1 year. 
1030-179 Coating of lntracoronary Stents With AC133+ 
Endothelial Progenitor Cells 
Ralf Koester, Markus Guckenbiehl, Ursula Gehling. Sonja Loges, Wulf Ito, Jan Kaehler, 
Dieter Hossfeld. Walter Fiedler. Thomas Meinertz, Thomas Muenzel, University Hospital 
Eppendorf, Hamburg, Germany 
Background: Rapid regeneration of endothekum after coronary stenting reduces resteno- 
sis and thrombosis. Endothelialization may be delayed after treatment with brachyther- 
apy or drug eluting stents. Endothelial progenitor cells (EPC) have a high regenerative 
potential which could enhance reendothelialization at sites of stenting. The aim of these 
experiments was to identify an optimal stent coating for adherence and growth of EPC. 
Methods: ACl33+ EPC were isolated from leukapheresls products. Mononuclear cells 
were isolated by density gradient centrifugation, incubated with AC133-conjugated 
microbeads and processed through a magnetic column. Purified EPC were cultivated in 
IMDM with supplements. 316L steel stents, coated with heparin, alumlnium oxide, 
fibronectin, vitronectin, osteonectin, collagen type I and IV, laminin and uncoated 316L 
steel were incubated with EPC for two weeks. Cell layers were evaluated by microscopy. 
Cell density was scored in 4 categories according to visual assessment of mean cell den- 
slty within three representative microscopic fields and analysis in quadriplets (categories: 
1: O-20; 2: 21-40; 3: 41-60; 4: 61-80 cells/field). 
Results: Within one week of culture EPC became adherent on heparin-, aluminium 
oxide-, fibronectin-, vitronectin-, osteonectin- and collagen-coated stents, whereas there 
was no visible cell attachment to uncoated 316L steel. The highest numbers of cells were 
counted on hepann-. aluminium oxide-, and collagen type IV-coated stents (>41 cells! 
field), whereas cell numbers were significantly lower on collagen type I- and vitronectin- 
coated stents (>21 cells/field). Lowest numbers or no cells were detected on osteonectin- 
, laminin-coated stems and on 316L stents without coating (>O cells/field). Morphological 
features revealed AC133-derived cells grown to confluence as endothelium. 
Conclusions: Endothelial progenitor cells are suitable for coating of coronary stems. 
Stent coating with heparin or aluminium oxide enhances their attachment and growth. 
Stent coating with progenitor cells may offer therapeutic potential in irradiated lesions or 
lesions treated with antiproliferative drugs. 
1030-l 80 The Impact of Sirolimus-Eluting Stents on the Outcome 
of Patients With Bifurcation Lesions 
Kenqo Tanabe, Pedro A. Lemos, Chl-hang Lee, Muzaffer Degertekin, Evelyn Regar, Akis 
C. Aramoatzis. Ron T. van Domburo. Pim de Fetier. Willem J. van der Glessen, Georqe 
Sianos, bieter C. Smits, Paul Cum&s, Arno R;iter. Francesco Saia, Patrick W. _ 
Serruys, Thoraxcenter, Rotterdam, The Netherlands 
Background: Although stents have improved procedural success rate, the treatment of 
bifurcation lesions is still problematic with an increased restenosis rate and need for 
repeat revascularizatin. Sirolimus-eluting stems (SES) have recently proved to virtually 
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eliminate in-stent restenosis in selected simple lesions (FIM. RAVEL trials). The aim of 
this study is to investigate the efficacy of SES in the treatment of bifurcation lesions. 
Methods: Since ld” April 2002 it is the policy of our institution to utilize the SES as a 
device of choice for all percutaneous interventions, with no clinical or anatomical exclu- 
sion criteria. The patients with bifurcation lesions are being included in this study. The fol- 
low-up angiography will be performed at 6 months after procedure. Results: Up to 161h 
August 2002, 44 patients with 44 bifurcation lesions have been treated with SES. The 
mean age was 61 years old and 13 patients (29.5%) were diabetic. All patients under- 
went SES deployment in both vessels. The baseline QCA results are present in the table. 
So far, there has been one target lesion revascularization 5 weeks after procedure, how- 
ever it is noteworthy that the restenosis occurred at the ostium of a side branch that was 
not covered with SES. The clinical outcomes and follow-up QCA results will be available 
at the time of presentation.Conclusions In this study, the impact of sirolimus-eluting 
stents on the outcome of patients with bifurcation lesions in the “real world” experience 
will be reported. 
Parent vessel side branch 
Pre reference diameter (mm) 2.84 - 0.56 2.31 - 0.54 
Pre minimum lumen diameter (mm) 0.76 - 0.59 0.65 - 0.50 
Post feference diameter (mm) 2.66 - 0.56 2.33 - 0.54 
Postminimum lumen diameter(mm) 2.36 -0.54 1.98 - 0.54 
1030-I 81 The Frequency and Consequences of Angiographic 
Aneurysms After Sirolimus-Eluting Stents: Results from 
SlRliJS 
Martin B. Leon, Jeffrey W. Moses, Giora Weiss, Paul S. Teirstein. Peter Fitzgerald, David 
R. Holmes, Jeffrey J. Popma. Cardiovascular Research Foundation, New York, NY 
Background: Angiographic aneurysms are observed after control bare metal stems 
(CS) in < 1% of pts and thusfar haven’t been associated with deleterious clinical out- 
comes. The marked anti-proliferative effects of sirolimus-eluting sterns (SES) raise con- 
cerns regarding potential vessel wall thinning and an increase in aneurysm formation. 
Methods: In the randomized double-blind SIRIUS trial (1058 pts), 8-month angiographic 
follow-up (FU) was obtained in 66% (702 pts). Angiographic aneurysms were defined as 
treatment site vessel diameter 2 1.5X the normal reference diameter (either at baseline 
or at FU) and all patients were assessed for clinical events (up to 9 months). 
Results: Aneurysms were found at FU in 6 pts (0.9%); 4 pts with CS (1.1%) and 2 pts 
with SES (0.6%). In the 4 CS aneurysms 0 FU, 2 were present at baseline and 
morhphology was fusiform ectasia in 2 (both multiple stents), and eccentric focal (<IO 
mm length) outpouching in 2 (1 proximal to RCA stent). In the 2 SES aneurysms @ FU, 
none were present at baseline and morphology was fusiform ectasia in 1 (3 SES after 
long RCA dissection) and eccentric focal outpouching in 1 (within RCA SES). In the 1 
case of SES focal outpouching, IVUS exam revealed.clear incomplete apposition at FU 
(flush apposition at baseline) with positive remodeling. Although 2 pts with angiographic 
aneurysms in CS pts had Res at FU, no pt in either group had adverse clinical events 
(death, MI. or stem thrombosis) during FU. 
Conclusions: Results from the SIRIUS angiographic analysis indicate that aneurysms at 
FU are (1) extremely infrequent (- 1%) with both CS and SES; (2) commonly were 
present at baseline and often are seen as diffuse fusiform ectasia; (3) are not associated 
with important clinical events (9 months FU). Thus, there are no objective findings to sug- 
gest that SES confer added risk of aneurysm formation and subsequent clinical events, 
1030-l 82 Platelet Activation After Stenting With Heparin-Coated 
Versus Noncoated Stents 
Paul A. Gurbel, Kevin P. Bliden, Bonnie L. Hi&t, Sinai Center for Thrombosis Research, 
Baltimore, MD 
Objectives: The purpose of the study was to investigate the effect of heparin coating on 
platelet activation following coronary artery stenbng. Background: In animal models hep- 
arin coating reduces platelet aggregation induced by coronary stenting. However, 
reduced platelet activation has never been demonstrated in humans. Methods: In a pro- 
spective randomized study of 50 consecutive elective patients, platelet activation was 
analyzed by measuring aggregation and surface receptor expression at baseline and at 2 
hours, 24 hours, 5 and 30 days following implantation of either heparin-coated or non- 
coated Bx velocity stent(s). Results: Platelet activation as measured by 24 hour expres- 
sion ( mean fluorescence intensity) of active glycoprotein (GP) Ilb/llla, and total GP llbi 
Illa. was decreased following implantation of a hepadn coated stent as compared to bare 
stents (10.3 f 6.1 vs 6.7 * 2.1, p=.O14 for active GPllb/llla and 382*101 vs 306+ 88, 
p=.Ol for total GPllb/llla). A trend at 30 days post-stentlng of lower total (383&150 vs 
296*86, ~~07) and active GP Ilb/llla expression (10.3i6.9 vs. 7.5k2.9, p=.15) were also 
observed with the heparin-coated stent. Aggregation and stimulated p-selectin did not 
differ between stent types. Conclusion: Elective stenting wtth a heparin-coated stent is 
associated with less early expression of GP Ilb/llla on circulating platelets as compared 
to revascularization with a bare stent of the same design. These findings have direct 
implications on the risk of subacute thrombosis and deserve further investigation 
1030-l 83 Sirolimus-Eluting Stent for the Treatment of Bypass 
Graft Disease: The Initial U.S. Experience 
Marco A. Costa, Jeffrey W. Moses, Martin B. Leon, Paul S. Teirstetn, Steven Yakubov, 
Andrew J. Carter, Tim A. Fischell, Paul Gilmore, Theodore A. Bass, University of Florida, 
Jacksonville, FL 
Background: Stenting has provided limited success in the treatment of saphenous vein 
grafts (SVG) as in-stent restenosis (ISR) and adverse clinical events remain a challenge. 
While brachytherapy has offered clear benefit in this high-risk population, outcomes 
remain suboptimal. The efficacy of Sirolimus-eluting stents in native coronary arteries is 
proven, however its application in bypass grafts remains to be determined. We report the 
first series of patients in the United States with graft disease treated with sirolimus-eluting 
stents as part of the compassionate use SECURE trial. 
Methods: Compassionate use of sirolimus-eluting stenting was indicated for patients 
with a serious disease or condition for which there was no acceptable alternative treat- 
ment available. To date, 80 patients have been enrolled in the SECURE study. Follow-up 
agiography will be repeated in all patients with prior brachytherapy failure. 
Results: Nineteen patients with bypass graft disease have been enrolled so far. Patient 
characteristics include: mean age 65 years, male 91%. prior myccardial infarction 55%, 
smokers 82%, diabetes 9%, hypertension 91% and hyperlipidemia 91%. Twenty-two per- 
cent presented with unstable angina. All patients had previous angioplasty. Seventeen 
lesions were treated in 15 grafts analyzed to date. Nine target vessels underwent previ- 
ous brachytherapy. Bypassed vessels were: RCA 29%, LAD 36%, Circumflex 29%. oth- 
ers 7%. Mean reference vessel diameter was 3.16mm, lesion length was 15mm. Mean of 
1.5 stents were implanted in each graft. There were no deaths up to 30 days in the first 
11 patients. Adjudicated in-hospital and a-month updated data will be presented. 
Conclusion: Implantation of sirolimus-eluting stents in high-risk patients is feasible. This 
may represent an important treatment option for patients with bypass graft disease. 
1030-l 84 Use of the Sirolimus Drug-Eluting Stent for Real World 
Coronary Lesions The Milan Experience: Results of the 
First 400 Lesions 
Vassilis Spanos Goran Stankovic, Flavio Airoldi, Matteo Montorfano, Nicola Corvaja. 
Francesco Liistro, Alaide Chieffo, Maryuri Segura, Davide Tavano, Carlo Di Mario, 
Antonio Colombo, Centro Cuore Columbus, Milan, Italy, San Raffaele Hospital, Milan, 
Italy 
Background: Positive results from the use of the Sirolimus drug-eluting stent 
(CYPHERTM, Cordis) in clinical trials addressing selected lesions have been published. 
We reporl our experience with the use of the Cypher stent in everyday clinical practice. 
Methods: We included all lesions treated with the Cypher stent in Milan between 15 of 
April and 30 of August 2002. Major adverse cardiac events (MACE) were defined as 
death, Q-wave myocardial infarction or target lesion revascularizatron. 
Results: Cypher stents were implanted in 217 patients (71% consecutive) to treat 418 
lesions. Three hundred fifty-three (84.5%) lesions were complex (ACClAHA classification 
82 or higher); 85 (20.3%) were in-stent restenosis and 42 (10.0%) chronic total occlu- 
sions. We utilized 2.2t1.6 Cypher stents per procedure (1.2~0.5 per lesion). Intravascu- 
lar ultrasound guidance was used in 67 (16.0%) lesions. The reference vessel size was 
2.8*0.5mm, the minimal lumen diameter (MLD) 0.79*0.48mm and the mean lesion 
length 18.5+13.8mm. 
The total length of Cypherstents used per lesion was 28.0+16.2mm. The maximum infla- 
tion pressure used was 15.7+3.4 atm and the balloon to artery ratio 1.1*0.3. The post- 
procedure MLD was 2.81*0.47mm, resulting in acute gain of 2.0*0.6mm. 
The clinical success rate was 99%. One patient required urgent coronary artery bypass 
surgery and died the next day and one had a Q-wave myocardial infarction during the 
procedure. 
Clinical follow-up at 1.720.5 months has been completed in 176 patients (97.8%) without 
detection of any other MACE. Six-month clinical follow-up will be available at the time of 
presentabon. Follow-up coronary angiography is planned for all patients nine months 
post-procedure and it is estimated to be accomplished in about 250 lesions at the time of 
presentation. Conclusions: The implantation of Cypher stents in “real world lesions”, 
aiming to completely cover the diseased segment, results in high stented vessel lengths. 
Thirly days complications are low without an increase in thrombosis, despite usage of 
long and multiple stents. We will see if follow-up results are in accordance with prior find- 
ings in less complex lesions. 
1030-l 85 Is There Any Arterial Toxic Effect After Overlapping 
Siroiimus-Eluting Stents? 
Alexandre A. Abizaid, Juan S. Munoz, Ana C. Seixas, Andrea S. Abizaid, Fausto Feres, 
Luiz A. Mattes, lbraim Pinto, Rodolfo Staico, Luiz F. Tanajura, Aurea J. Chaves, 
Marinella Centernero, Amanda Sousa, Gary S. Mints, Jose Eduardo M. Sousa, Institute 
Dante Pazzanese of Cardiology, Sao Paula, Brazil 
Background: Drug-eluting stents reduce first-time in-stent restenosis (ISR) and are 
being investigated as a treatment for ISR after bare-metal stenting. However, it remains 
unclear whether overlapping drug-eluting stents (and effectively doubling the drug dose) 
has a toxic effect on the vessel wall. 
Objective: The purpose of this study was to analyse the one-year IVUS findings after 2 
overlapping Sirolimus-eluting stems were implanted in patients with native artery ISR 
lesions. 
Methods: Cf 25 patients in the ISR Sirolimus registry, 8 had a lesion length requiring 2 
stents for full lesion coverage. Per protocol, these stents were implanted with a >l mm of 
overlap. Volumetric intravascular ultrasound (IVUS) was performed immediately and one 
year after implantation. 
